INOVIO Pharmaceuticals Files Q1 2025 10-Q

Ticker: INO · Form: 10-Q · Filed: May 13, 2025 · CIK: 1055726

Inovio Pharmaceuticals, INC. 10-Q Filing Summary
FieldDetail
CompanyInovio Pharmaceuticals, INC. (INO)
Form Type10-Q
Filed DateMay 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

INOVIO's Q1 2025 10-Q is in. Check financials.

AI Summary

INOVIO Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business developments are presented within this report.

Why It Matters

This filing provides investors and stakeholders with the latest financial health and strategic direction of INOVIO Pharmaceuticals, crucial for understanding its current market position and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, INOVIO faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 10-Q filing?

This 10-Q filing provides a quarterly update on INOVIO Pharmaceuticals, Inc.'s financial performance and business operations for the period ending March 31, 2025.

What is the company's full name and Central Index Key (CIK)?

The company's full name is INOVIO PHARMACEUTICALS, INC., and its Central Index Key is 0001055726.

What is the fiscal year end for INOVIO Pharmaceuticals, Inc.?

INOVIO Pharmaceuticals, Inc.'s fiscal year ends on December 31.

What is the business address of INOVIO Pharmaceuticals, Inc.?

The business address is 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING, PA 19462.

What SEC Act is this filing under?

This filing is made under the Securities Exchange Act of 1934 (SEC Act: 1934 Act).

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding INOVIO PHARMACEUTICALS, INC. (INO).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing